MedTrace Logo

Diamorphine or Alfentanil for Subcutaneous Use in Hospice In-patients?

NCT01049672 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-03-17

No results posted yet for this study

Summary

OBJECTIVES:

How does Alfentanil compare with the standard drug Diamorphine for subcutaneous analgesia in the palliative care setting?

STUDY DESIGN:

An open-label pilot comparison between alfentanil and diamorphine for palliative care patients who require subcutaneous opioids.

Conditions

Interventions

DRUG

Alfentanil

Titrated to a maximum dose of 50mg in 24 hours subcutaneously

DRUG

Diamorphine

Titrated to a maximum dose of 500mg in 24 hours given subcutaneously

Sponsors & Collaborators

  • Gloucestershire Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Paul Perkins, MBBCh FRCP · Gloucestershire Hospitals NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01049672 on ClinicalTrials.gov